Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
carboplatin + cisplatin + docetaxel + paclitaxel
- Development stage
- Phase 3
- Lead developer
- Johnson Matthey
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
This is a combination of four chemotherapy drugs that includes two platinum agents (carboplatin and cisplatin) and two taxane agents (docetaxel and paclitaxel). While these drugs are not typically used together as a four-drug regimen, they are commonly used in various two-drug platinum-taxane combinations for treating different types of cancer. The platinum agents (carboplatin and cisplatin) work by forming DNA crosslinks that inhibit DNA repair and synthesis in cancer cells, while the taxanes (docetaxel and paclitaxel) work by disrupting microtubule function during cell division.
02
Targets
DNAMicrotubule
Beyond the preview
Go deeper on carboplatin + cisplatin + docetaxel + paclitaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on carboplatin + cisplatin + docetaxel + paclitaxel.